YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
* TELA Bio (TELA [https://seekingalpha.com/symbol/TELA]) on Monday said Roberto Cuca, Chief Operating Officer and Chief Financial Officer, will step down from the role. * The company also announced a headcount reduction of approximately 20…
Image source: The Motley Fool. DATE Monday, Aug. 10, 2026, at 4:30 p.m. ET CALL PARTICIPANTS Chairman-Joe Capper Chief Executive Officer-Heather Getz President-Jeffrey Blizard Chief Operating Officer and Chief Financial Officer-Roberto E.…
MALVERN, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, announced that the Board of D…
MALVERN, Pa., July 29, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compan…
MALVERN, Pa., July 20, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compan…
Earnings Call Insights: TELA Bio (TELA) Q1 2026 MANAGEMENT VIEW * "Last quarter, we laid out a framework detailing the decisive steps we have taken to reset our commercial strategy, and Q1 results show early proof points that our strategic…
MALVERN, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first…
BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $0.88 per share a year ago. These figures are adjusted for non-recurring items. Thi…
TELA Bio, Inc. MALVERN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced t…
TELA Bio, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Performance and Operational Evolution Achieved 16% full-year revenue growth and record fourth-quarter results despite undergoing a fundamental rebuild of the commercial organiza…
Earnings Call Insights: TELA Bio, Inc. (TELA) Q4 2025 MANAGEMENT VIEW * Antony Koblish, Co-founder, CEO & Director, highlighted that 2025, particularly the third and fourth quarters, was a period of "meaningful strategic change across the…
Image source: The Motley Fool. DATE Tuesday, March 24, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Antony Koblish President — Jeffrey Blizard Chief Financial Officer — Roberto E. Cuca Chief Commercial Officer — Jim Hag…
Image source: The Motley Fool. DATE Tuesday, March 24, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Antony KoblishPresident — Jeffrey BlizardChief Financial Officer — Roberto E. CucaChief Commercial Officer — Jim Hagen…
Astrana Health, Inc. (ASTH) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to a loss of $0.15 per share a year ago. These figures are adjusted for non-recurring i…
MALVERN, Pa., Feb. 20, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compen…
TELA Bio, Inc. MALVERN, Pa., Feb. 20, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced…
MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compen…
TELA Bio, Inc. MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced…
[Meshes For Hernia] PhotoGraphyKM * Tela Bio (TELA [https://seekingalpha.com/symbol/TELA]) has filed a lawsuit accusing Becton, Dickinson (BDX [https://seekingalpha.com/symbol/BDX]) of stymying competition in the US market for surgical her…
TELA Bio, Inc. MALVERN, Pa., Dec. 12, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced…
MALVERN, Pa., Nov. 19, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will partic…
(RTTNews) - Several small-cap biotech and therapeutics companies posted notable gains in Monday's after-hours trading session, driven by earnings updates, financial guidance, and regulatory developments. Inotiv, Inc. (NOTV) surged 36.61% i…
MALVERN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compen…
Earnings Call Insights: TELA Bio (TELA) Q3 2025 MANAGEMENT VIEW * Antony Koblish, CEO, emphasized the company's continued execution on expanding its commercial footprint, improving operating discipline, and strengthening its patient-centri…
* TELA Bio (TELA [https://seekingalpha.com/symbol/TELA]) priced [https://seekingalpha.com/pr/20307445-tela-bio-announces-pricing-of-13_0-million-underwritten-registered-direct-offering-of-common] an underwritten registered direct offering…
MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the pricing of an underwritten reg…
MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the third…
Company Logo The United States Breast Reconstruction Market is projected to grow from US$ 1.02 billion in 2024 to US$ 1.74 billion by 2033, with a CAGR of 6.1% from 2025 to 2033. Key factors driving this growth include rising breast cancer…
MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment…
Earnings Call Insights: TELA Bio, Inc. (TELA) Q2 2025 MANAGEMENT VIEW * CEO Antony Koblish opened by highlighting that Q2 2025 was "the first quarter to exceed $20 million in revenue, stemming from the highest global unit sales in the quar…
MALVERN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the secon…
TELA Bio, Inc. MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced…
MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compen…
Earnings season continues, with several notable companies set to release their financial results for the upcoming trading day. Leading the pack are mining giant Barrick Gold, biopharmaceutical company Roivant Sciences (NASDAQ:ROIV), and he…
MALVERN, Pa., July 23, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will partic…
MALVERN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compan…